Reagan-Udall Foundation Cooperates with FDA for CTP Investigation

Aug.06.2022
Reagan-Udall Foundation Cooperates with FDA for CTP Investigation
The Reagan-Udall Foundation selects the US for a 60-day FDA review of the Center for Tobacco Products.

The Reagan-Udall Foundation, a collaborative partner with the FDA in investigating CTP, has chosen the United States of the Clinton era.


According to Politico, Jane Henney, the commissioner of the Food and Drug Administration (FDA), will lead a 60-day review of the agency's food safety and tobacco division (CTP) operations. Henney is the first female leader of the Reagan-Udall Foundation and has previously worked at the FDA. This news has not been officially announced yet.


US Food and Drug Administration Commissioner, Robert Califf, has taken this action in order to overcome several controversies during his second term. These controversies include his issuance of a marketing denial order (MDO) to e-cigarette manufacturer Juul Labs, which he later had to rescind.


To learn more about legal disputes between the FDA and electronic cigarette companies, click on the "FDA and Electronic Cigarette Company Legal Dispute Summary" special feature, continuously updated by 2FIRSTS.


Statement:


This article is compiled based on third-party information and is intended for industry exchange and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot verify the authenticity or accuracy of its content. Its translation is intended for industry exchange and research purposes only.


Due to limitations in translation ability, the compiled article may not perfectly reflect the original text. Therefore, it is recommended to refer to the original text for accuracy.


2FIRSTS maintains complete consistency with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and positions.


Copyrights for compiled information belong to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.